Tarsus Pharmaceuticals, Inc., founded in 2016 and headquartered in Westlake Village, California, is a clinical‐stage biopharmaceutical company dedicated to developing novel therapies for eye diseases. The company’s research and development efforts concentrate on small‐molecule treatments designed to address unmet needs in the anterior segment of the eye, including inflammatory, infectious and degenerative conditions.
The company’s lead investigational product, lotilaner ophthalmic solution (TP-03), is being evaluated for the treatment of Demodex blepharitis, a common but often underdiagnosed eyelid disorder. Tarsus also has a pipeline of additional candidates, including TP-01, a kinase inhibitor for post-surgical ocular pain and inflammation, and TP-04, which targets meibomian gland dysfunction in dry eye disease. These programs leverage proprietary mechanisms of action aimed at providing more effective and convenient treatment options than currently available therapies.
While Tarsus initially focuses its clinical and commercial efforts on the U.S. market, the company has plans to pursue regulatory submissions in Europe and other international regions. Its global strategy includes partnerships with leading ophthalmology centers and contract research organizations to advance late-stage trials. The leadership team is headed by President and Chief Executive Officer F. West Sisselman, whose more than 25 years of biopharmaceutical experience are complemented by executives with deep expertise in clinical development, regulatory affairs and commercialization.
AI Generated. May Contain Errors.
